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ABSTRACT
Peritoneal carcinomatosis (PC) is a common evolution of cancer of the gastrointestinal tract, and has been tra-
ditionally regarded as a terminal disease with short median survival. During the last 20 years, due to its fa-
vourable oncologic results, a new loco-regional therapeutic approach, combining cytoreductive surgery with
intra-operative intraperitoneal chemotherapy has achieved an important development. After liver metastatic
disease, peritoneal carcinomatosis is the second most frequent cause of death in colorectal cancer patient is de-
fined as a stage IV tumour which prognosis is the worst. The extent of peritoneal carcinomatosis is, however,
difficult for assessment preoperatively, and precise evaluation is most often performed during surgical explo-
ration. Cytoreductive surgery associated with chemotherapy for the treatment of peritoneal carcinomatosis
should be performed in young patients with limited and resectable carcinomatosis, in specialized institutions
involved in the management of peritoneal surface malignancies.
Key words: colorectal cancer, peritoneal carcinomatosis, cytoreductive surgery
INTRODUCTION
Peritoneal carcinomatosis (PC) is, liver metastatic disease,
the second most frequent cause of death in patients with
colorectal cancer (CRC). The peritoneal surface is involved
in 10%-30% (1-3) of patients with CRC and in roughly
7%-8% (3,4) at the time of primary surgery, in 4%-19% of
cases during follow-up after curative surgery, in up to 44%
of patients with recurrent CRC who require relaparotomy,
and in 40%-80% of patients who succumb to CRC (4).
However, in the 25% of patients with metastatic disease,
the peritoneal cavity seems to be the only site of diffusion
even after extensive diagnostic investigations (5). Pres-
ently, this last group of patients is commonly classified and
treated as stage IV CRC, and there is no published data that
outlines the impact of new therapeutic regimens on survival
(6) and therefore research into new therapeutic approaches
is widely justifiable and favourable. The PC occurs by a se-
quence of events: the spreading of cancer cells in the
peritoneal cavity, their adhesion to the mesothelial surface
and the invasion of the subperitoneal space for proliferation
and vascular neogenesis (7). The high incidence of tumour
implantation on the peritoneal surface in CRC can occur by
intraperitoneal tumour emboli as a result of serosal penetra-
tion, or can be the consequence of surgical management
through leakage of the malignant cells from the lymphatic
vessels or through their dissemination due to tumour
trauma because of dissection, with subsequent fibrin en-
trapment and tumour promotion of the entrapped cells (8).
We review the accessible literature for reports about treat-
ment of peritoneal carcinomatosis in patients with diag-
nosed colorectal cancer. We searched the MEDLINE data-
base with the followed keywords: Colorectal cancer;
Peritoneal carcinomatosis; Cytoreductive surgery. We
found 33 suitable articles which were reviewed and used
for our study.
The three principal studies (2,3,9) dedicated to the natural
history of peritoneal carcinomatosis from CRC confirmed a
poor prognosis with a median survival ranging between 6
and 8mo and no 5-year survivors. Chu et al (2) reported, in
a series of 100 patients with PC of nongynecologic tu-
mours, a median survival of 6 mo. Sadeghi et al (3), in a
multi-centre prospective study reported 118 patients with
PC from CRC with amedian survival of 5.2mo. In a retro-
spective analysis (9) of 3019 patients with CRC, 13% of
these presented carcinomatosis and had a median survival
of 7 mo. Verwaal et al (10), in a phase II randomized con-
trolled trial of 50 patients who were treated with systemic
chemotherapy and palliative surgery obtained an overall
median survival of 12.6 mo with a 2-year survival rate of
18% and a median time to disease progression of 7.6 mo.
Cytoreductive surgery (CRS) and
intraperitoneal chemotherapy (IPEC)
AsreportedbyEsquiveletal (6), in the lightofanewaggressive
approachbasedon thecombinationofCRSandIPEC, thestory
of peritoneal carcinomatosis can probably be rewritten like the
story of colorectal liver metastases. In the 1930s, Meigs (11)
was the first to advocate CRS followed by adjuvant radiother-
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apy in patientswith ovarian cancerbut with poor results. Subse-
quently Munnell (12) and Griffiths (13), between the 1960s and
1970s, demonstrated that better survival rates could be achieved
bymoreextensivesurgeryand that the sizeof residualdisease is
the most important prognostic factor (11). In 1980s, Spratt. was
the first to report, after an experimental study with hyperthermic
peritoneal perfusion in dogs (14), the results of CRS followed
by IPEC using thioTEPA in a patient with pseudomyxoma
peritonei (15). After this first clinical report, Sugarbaker et al
(16,17) finally in the 1990s proposed and improved CRS and
perioperative intraperitoneal chemotherapy as a possible treat-
ment, initially for peritoneal dissemination of the appendiceal
neoplasms and diffuse malignant peritoneal mesothelioma (14)
and successively, for patients with PC from various gastrointes-
tinal tumours.Thiswasbasedon therealization thatPCisa form
of locoregional cancer dissemination rather than a systemic
spread of the disease. Perioperative intraperitoneal chemother-
apy consists of the intraperitoneal administration of drugs in a
large volume of fluid either during the operation or postopera-
tively (16). Intraperitoneal chemotherapy can increase local ex-
posure of the peritoneal surface to pharmacologically active
molecules, especially those of high molecular weight
(Mitomycin C, 5-FU, Doxorubicin, Cisplatin, Paclitaxel and
Gemcitabine) resulting in a more uniform distribution through-
out the abdominal cavity (16). This treatment can also be per-
formed under hyperthermicconditions. Hyperthermia, associ-
ated with intraperitoneal chemotherapy, presents several advan-
tages; it has a direct cytotoxic effect and enhances the activity
and penetration depth of many cytotoxic drugs (17-19). Be-
cause it is estimated that the optimal target of
thermochemotherapy is limited to few millimetres, is manda-
tory to resect all the macroscopic disease (20). According to
Sugarbaker, the peritoneumcan be divided into six parts, so be-
tween one and six peritonectomy procedures may be required,
including visceral and parietal peritonectomies (16). Subse-
quently, when the resection of the cancer is complete, some
catheters and suction drains are placed through the abdominal
wall to permit perfusion, with open or closed abdomen tech-
niques or with peritoneal cavity expander or a semi-opened or
semi-closed technique. Elias, in a phase II study, using
Oxaliplatin after administration of 5-FU and Leucovorin iv be-
fore IPEC, reported no case of mortality, 40% morbidity and a
5-year overall survival of 48.5% (median survival 60.1 mo)
witha73%rateof recurrenceat14mo(20) Inanother study, the
same author, in a retrospective comparison of IPEC with
Oxaliplatin vs standard systemic chemotherapy, found
thatmedian survival. rate of the IPEC group was significantly
better than that of the other group (62.7 mo vs 23.9 mo) (20).
Survival after CRS and IPEC
In the last decade, an increasing number of prospective
studies investigated the effectiveness of the CRS and IPEC
in the management of PC of colorectal origin. Meigs et al.
(11) were the first who in 2003 conducted a randomized
controlled trial comparing the efficacy of CRS and IPEC
with systemic chemotherapy and surgery. This trial clearly
demonstrated longer survival in the combined treatment
group with a median survival of 22.3 mo vs 12.6 mo ob-
tained in the control arm. Subsequently, Jacquet et al (17) in
1998, in a multi-institutional registry study from 28 interna-
tional treatment centres, showed that the median survival
was 19 mo and 3-year survival was 39% after CRS and
IPEC for 506 patients with colorectal peritoneal
carcinomatosis. However at present, the clinical outcomes,
in the literature, vary considerably: the median survival
from12 to 32mo, with 1-year, 2-year, 3-year and when re-
ported 5-year survival rates ranging from 65% to 90%,
25% to 60%, 18% to 47% and 17% to 30%, respectively
(4). Univariate and multivariate analyses of most series of
patients with PC of colorectal origin revealed several clini-
cal, surgical and pathologic factors predictive of survival
(4). Clinical characteristics that have been correlated, in
univariate analyses with an improved survival, are female
gender, younger age and good clinical performance status
(4). Surgical factors that have been correlated with survival
are the extent of carcinomatosis encountered at laparotomy,
the completeness of resection, bowel obstruction, the pres-
ence of ascites and the presence and resection ofmetastatic
disease to the liver (4). Finally, the pathologic factors that
have been correlated with impaired survival include site of
the primary tumour, poor tumour differentiation, signet cell
histology and lymph node involvement. However, the re-
sults of multivariate analyses on the abovementioned
clinicopathologic factorswere reported in 5 publications; in
4 of these, the extent of disease [measured by Peritoneal
Cancer Index (PCI)] and the completeness of resection
were the factors most related to treatment success and
survival (4). Patients with localization in six or seven re-
gions of the abdomen had a poor prognosis, with a median
survival of 5.4 mo vs 29 mo in those with a lower number
of regions affected (7). In a recent retrospective study, in 70
patients, da Silva and Sugarbaker demonstrated, by
univariate analysis, that the patients with a PCI < 20 had a
median survival of 41 mo compared with 16 mo for pa-
tients with PCI > 20 (P =0.004). Verwaal et al. (10), using
their seven regions system, demonstrated that the survival
benefit was low in patients with more than five regions in-
volved, with a greater correlated morbidity. The complete-
ness of resection was also linked to survival. Median sur-
vival following complete resection of all macroscopic dis-
ease varied from 17.8mo to 39.0mo, whereas the re-
ported-year survival rates varied from 20% to 54% while
median survival, after incomplete resection, resulted
inmedian survival times of 12.5-24mo,with 5-year survival
rates between 10% and 29%.Whenmacroscopic disease
ofmore 5 mm in diameter had to be left behind, the reported
median survival varied between 5 and 12mo and none of
these patients survived for 5 years (4).
Morbidity and mortality after CRS and
IPEC
CRS followed by IPEC carries a postoperative morbidity of
14% to 55% and a treatment-related mortality of 0% to 19%,
which seem to be related to the extent of surgery as a func-
tion of peritoneal involvement rather than to the IPEC (4).
Elias et all. (20) suggested that there is a learning curve asso-
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ciated with the procedure for achieving an acceptable mor-
bidity rate and Witkamp affirms that postoperative compli-
cations could be resolved favourably inmost cases with cor-
rect patient selection and adequate postoperative care (8).
CONCLUSION
Arecent international conference was convened and a con-
sensus statement on the appropriate use of CRS and IPEC
was developed and adopted by the Peritoneal Surface Ma-
lignancy Group in an attempt to standardize the indications
and techniques for this treatment (6). However we retain,
according with the conclusion of Griffiths in his recent re-
view (13), that a large prospective randomized controlled
trial is needed to compare long-term and progression free
survival under best available systemic therapy with or with-
out CRS and IPEC. The selection of the patients for the
management of peritoneal carcinomatosis associating CRS
and IPEC is based on two main directions. From one point
of view, patients have to be able to support an aggressive
treatment associating surgery and chemotherapy. Secondly,
tumors have to be completely resectable. With regard to the
high level of postoperative mortality and morbidity and the
oncological results, these principles are particularly true for
the treatment of peritoneal carcinomatosis. The selection of
patients has to be strictly performed to improve the out-
comes. CRS associated with IPEC for the treatment of
peritoneal carcinomatosis should be performed for young
patients with limited and resectable carcinomatosis, in
specialized institutions involved in the management of
peritoneal surface malignancies.
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